美国FDA同意审查Moderna修改后的流感疫苗申请

Core Viewpoint - Moderna's flu vaccine application has been accepted for review by the FDA, reversing an earlier rejection, which indicates a potential advancement in the company's vaccine portfolio and market opportunities for older adults [1] Group 1: FDA Review and Approval - The FDA has agreed to review Moderna's flu vaccine application after initially rejecting it [1] - The company proposed a revised plan seeking full approval for adults aged 50 to 64 and expedited approval for those aged 65 and older [1] Group 2: Post-Market Research - Moderna plans to conduct post-market studies specifically targeting the elderly population following the vaccine's approval [1]